Show simple item record

dc.contributor.authorHalvorsen, Tarje Onsøien
dc.contributor.authorHerje, Martin
dc.contributor.authorLevin, Nina
dc.contributor.authorBremnes, Roy M.
dc.contributor.authorBrustugun, Odd Terje
dc.contributor.authorFløtten, Øystein
dc.contributor.authorKaasa, Stein
dc.contributor.authorSundstrøm, Stein Harald
dc.contributor.authorGrønberg, Bjørn Henning
dc.date.accessioned2018-02-01T13:53:17Z
dc.date.available2018-02-01T13:53:17Z
dc.date.issued2016-10-15
dc.description.abstractObjectives: <br> Concurrent chemotherapy and thoracic radiotherapy (TRT) is recommended for limited disease small-cell lung cancer (LD SCLC). TRT should start as early as possible, often meaning with the second course due to patient referral time and the fact that TRT planning takes time. Early assessment of response to the first course of chemotherapy may be a useful way to individualise treatment. The aims of this study were to assess tumour size reduction after the first chemotherapy-course, and whether this reduction was associated with outcomes in LD SCLC. <br>Material and methods: <br> A randomised trial comparing twice-daily (45 Gy/30 fractions) with once-daily (42 Gy/15 fractions) TRT, given concurrently with four courses of cisplatin/etoposide (n = 157) was the basis for this study. Tumour size was assessed on CT scans at baseline and planning scans for TRT according to RECIST 1.0. <br>Results: <br> CT scans were available for 135 patients (86%). Ninety-four percent had a reduction in tumour size after the first chemotherapy-course. The median reduction in sum of diameters (SOD) of measurable lesions was ÷16 mm (÷84 to +10 mm), corresponding to ÷18% (÷51 to +12%). Eighty-two percent had stable disease, 18% partial response. Reduction in SOD was significantly associated with complete response at first follow-up (OR: 1.05, 95% CI 1.01–1.09; p=0.013), PFS (HR: 0.97, 95% CI 0.96-0.99; p=0.001), and overall survival (HR: 0.98, 95% CI 0.96–1.00; p=0.010).<br> Conclusion: <br> Response from the first course of chemotherapy had a significant positive association with outcomes from chemoradiotherapy, and might be used to stratify and randomise patients in future studies.en_US
dc.descriptionAccepted manuscript version. Published version available at <a href=https://doi.org/10.1016/j.lungcan.2016.10.003> https://doi.org/10.1016/j.lungcan.2016.10.003 </a>en_US
dc.identifier.citationHalvorsen, T., Herje, M., Levin, N., Bremnes, R. M., Brustugun, O. T., Fløtten, Ø. (...) Grønberg BH. (2016). Tumour size reduction after the first chemotherapy-course and outcomes of chemoradiotherapy in limited disease small-cell lung cancer. Lung Cancer. 102:9-14.en_US
dc.identifier.cristinIDFRIDAID 1409790
dc.identifier.doi10.1016/j.lungcan.2016.10.003
dc.identifier.issn0169-5002
dc.identifier.issn1872-8332
dc.identifier.urihttps://hdl.handle.net/10037/12075
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.relation.journalLung Cancer
dc.rights.accessRightsopenAccessen_US
dc.subjectVDP::Medisinske fag: 700::Klinisk medisinske fag: 750::Onkologi: 762en_US
dc.subjectVDP::Midical sciences: 700::Clinical medical sciences: 750::Oncology: 762en_US
dc.subjectLungekreft / Lung canceren_US
dc.titleTumour size reduction after the first chemotherapy-course and outcomes of chemoradiotherapy in limited disease small-cell lung canceren_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record